Catalyst Dossier · compiled by CeliA 🧫

Praxis Precision Medicines, Inc. (PRAX)

Pharmaceutical Preparations · market cap $7.9B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Praxis Precision Medicine (PRAX) is a clinical-stage pharmaceutical company focused on neurological and psychiatric disorders, with a market cap of ~$9.1B and 116 employees. Its lead asset PRAX-562 is in Phase 3 for SCN2A Encephalopathy, while the pipeline spans epileptic encephalopathies, essential tremor, focal epilepsy, and major depressive disorder. The company holds $536M in cash (~18.7 months runway) and has generated no meaningful commercial revenue to date.

The catalyst path

2026-07-15 (est.)Phase 3 · 1.0mg/kg/day PRAX-562imp 9/10
2026-08-03Earningsimp 5/10
2026-12-15 (est.)Phase 3 · 1.0mg/kg/day PRAX-562imp 9/10
2027-01-15 (est.)Phase 3 · 40 mg/day vormatrogine for 12 weeksimp 9/10
2027-01-31PDUFAimp 7/10

Pipeline

Asset	Phase	Indication
Part A: 20 and 40 mg PRAX-944	Phase 2	Essential Tremor
PRAX-562	Phase 3	SCN2A Encephalopathy
10 mg PRAX-114	Phase 2	Major Depressive Disorder
100 mg PRAX-944	Phase 2	Essential Tremor
1mg elsunersen	Phase 3	Epileptic Encephalopathy
1.0mg/kg/day PRAX-562	Phase 3	Developmental and Epileptic Encephalopathy 1
40 mg/day vormatrogine for 12 weeks	Phase 3	Focal Epilepsy
30mg PRAX-628	Phase 2	Focal Onset Seizure
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks	Phase 3	Focal Seizure
PRAX-114	Phase 3	Major Depressive Disorder
PRAX-222 - Initial Dose	Phase 2	SCN2A-DEE

Price & technical context

3-month

-0.2%

6-month

+7.2%

12-month

+637.8%

52-wk range

$37.70–$357.13

vs 50-day MA

+1.3%

vs 200-day MA

+23.5%

Realized vol

129.0%

Max drawdown

-68.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PRAX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.